Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.00 USD
-0.12 (-1.48%)
Updated Jul 24, 2024 09:58 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Addex Therapeutics Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 3 | 4 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 2 | 1 | 3 | 4 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 23 | 20 | 17 | 0 |
Income After Depreciation & Amortization | -11 | -22 | -17 | -13 | 0 |
Non-Operating Income | 0 | 0 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 1 | NA |
Pretax Income | -12 | -22 | -17 | -14 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -12 | -22 | -17 | -14 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -22 | -17 | -14 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | -21 | -17 | -13 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -11 | -22 | -17 | -13 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.63 | 0.38 | 0.28 | 0.22 | 0.22 |
Diluted EPS Before Non-Recurring Items | -18.70 | -57.80 | -59.00 | -61.40 | -67.60 |
Diluted Net EPS (GAAP) | -18.71 | -57.84 | -59.08 | -61.44 | -67.60 |
Fiscal Year end for Addex Therapeutics Ltd Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.27 | 0.18 | 0.37 | 0.70 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.27 | 0.18 | 0.37 | 0.70 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.17 | 3.21 | 3.37 | 3.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.90 | -3.03 | -3.00 | -2.84 |
Non-Operating Income | NA | 0.06 | 0.02 | 0.02 | 0.01 |
Interest Expense | NA | 0.00 | 0.21 | -0.02 | 0.16 |
Pretax Income | NA | -0.84 | -3.22 | -2.96 | -2.98 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.84 | -3.22 | -2.96 | -2.98 |
Extras & Discontinued Operations | NA | -2.69 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.53 | -3.22 | -2.96 | -2.98 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.86 | 0.79 | 0.73 | 0.60 |
Diluted EPS Before Non-Recurring Items | NA | -1.37 | -4.06 | -4.07 | -5.00 |
Diluted Net EPS (GAAP) | NA | -4.12 | -7.99 | -0.20 | -5.34 |